Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Spinal Cord Series and Cases Année : 2017

Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder

Résumé

Urinary tract infections (UTI) are a major public health problem among spinal cord injury (SCI) patients. They frequently involve multidrug-resistant (MDR) bacteria. Ceftolozane/tazobactam (C/T) is a novel antibiotic combination approved for complicated intra-abdominal and UTI caused by Gram-positive and Gram-negative organisms, including some MDR strains. Little is known about the use of this agent for complicated febrile UTI occurring among SCI patients with neurogenic bladder due to MDR Pseudomonas aeruginosa (PSA).

Domaines

Bactériologie

Dates et versions

hal-01685434 , version 1 (16-01-2018)

Identifiants

Citer

Aurélien Dinh, Benjamin Davido, Ruxandra Calin, Julie Paquereau, Clara Duran, et al.. Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder. Spinal Cord Series and Cases, 2017, 3, pp.17019. ⟨10.1038/scsandc.2017.19⟩. ⟨hal-01685434⟩
54 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More